Lv41
571 积分 2021-02-20 加入
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?
2小时前
已完结
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial
6天前
已完结
Advances in sarcopenia: mechanisms, therapeutic targets, and intervention strategies
6天前
已完结
Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity
6天前
已完结
The therapeutic age of the neonatal Fc receptor
27天前
已完结
Subcutaneous delivery of monoclonal antibodies: How do we get there?
1个月前
已完结
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
1个月前
已完结
Depletion of mast cells with barzolvolimab, an anti‐KIT antibody, does not affect mast cell progenitors
1个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
1个月前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
1个月前
已完结
Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer
皖公网安备34019202002308
